BRANFORD, Conn. / Aug 08, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics technology company redefining protein analysis through single-molecule detection, today announced that it will be participating in the UBS Precision Medicine Frontiers Summit taking place at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA, August 13-14, 2025.
Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will be available for one-on-one meetings throughout the day on Thursday, August 14, 2025, and Jeff Hawkins will participate in the New Dimensions in Proteomics and Cellular Research panel on the same day from 8:15 – 8:50 AM Pacific Daylight Time.
About Quantum-Si Incorporated
Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.
Last Trade: | US$1.03 |
Daily Change: | -0.06 -5.50 |
Daily Volume: | 7,767,669 |
Market Cap: | US$188.040M |
August 05, 2025 June 17, 2025 June 10, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load